Migraine Drugs Market to Reach US$ 23.70 Billion by 2031 at 10.3% CAGR; North America Leads with 42% Share | Key Players Amgen, Eli Lilly, AbbVie

The Migraine Drugs Market reached US$ 10.90 billion in 2023 and is expected to reach US$ 23.70 billion by 2031, growing at a CAGR of 10.3% during the forecast period 2024-2031. Market growth is driven by the rising global prevalence of migraine disorders, increasing awareness and diagnosis rates, and the growing demand for effective acute and preventive treatment options. The introduction of novel drug classes such as CGRP inhibitors and gepants has significantly improved treatment outcomes and expanded the therapeutic landscape.

North America holds a major share of the market due to high disease awareness, strong healthcare infrastructure, and early adoption of innovative migraine therapies. Europe follows, supported by increasing healthcare spending and wider access to prescription migraine medications. The Asia-Pacific region is expected to witness strong growth during the forecast period, driven by improving healthcare access, rising urbanization-related migraine triggers, and expanding pharmaceutical distribution networks.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/migraine-drugs-market?sai-v

The migraine drugs market refers to the global industry focused on medications used to prevent and treat migraine headaches and associated symptoms.

Key Developments
✅ January 2026: In North America, expanded clinical use of CGRP monoclonal antibodies and gepants for both acute and preventive migraine management continued to grow, with strong uptake of therapies from Eli Lilly (emgality), Novartis (aimovig), Amgen/Novartis (ajovy), and AbbVie/Allergan (ubrelvy).

✅ January 2026: In Europe, healthcare payers expanded reimbursement for next-generation small-molecule CGRP receptor antagonists (gepants) and long-acting monoclonal antibodies, supporting broader access to preventive and acute migraine treatments from Biohaven (rimegepant), Pfizer (zavegepant), and Teva Pharmaceuticals (generic options).

✅ December 2025: In Asia-Pacific, increased adoption of multimodal migraine management strategies integrated digital therapeutic tools and patient support programs alongside drug therapies from Eli Lilly, Novartis, and Amgen to improve adherence and outcomes.

✅ December 2025: Globally, clinical evidence from late-stage studies reinforced the benefits of CGRP pathway inhibitors in reducing migraine frequency and severity, widening clinical acceptance of leading products from Biohaven, Eli Lilly, and AbbVie/Allergan.

✅ November 2025: In Latin America, awareness campaigns and guideline updates supported better diagnosis and treatment rates, enhancing use of established and novel migraine drugs from Pfizer, Novartis, and Teva Pharmaceuticals.

✅ October 2025: Worldwide, research continued into next-generation therapeutics targeting PACAP and other non-CGRP pathways, with early-stage programs progressing at companies including Amgen, Lilly, and Ionis Pharmaceuticals.

Mergers & Acquisitions
✅ January 2026: In the United States, Eli Lilly acquired a clinical-stage neuroscience biotech focused on innovative migraine therapeutic candidates targeting novel pathways to strengthen its CNS portfolio.

✅ December 2025: In Europe, Novartis completed the acquisition of a small-molecule neuromodulator developer aimed at migraine and related neurological conditions to expand its preventive therapy offerings.

✅ November 2025: In Asia-Pacific, Takeda Pharmaceutical Company secured rights to an emerging migraine prevention program to broaden its CNS and pain management portfolio across regional markets.

Key Players
Amgen Inc. | Tonix Pharmaceuticals | Teva Pharmaceuticals | Eli Lilly and Company | AbbVie Inc. | Pfizer Inc. | Lundbeck | Impel Pharmaceuticals Inc. | Currax Pharmaceuticals | Endo Pharmaceuticals Inc. | Others

Key Highlights
Amgen Inc. holds 21% share, driven by its strong CGRP-based migraine therapies, robust biologics expertise, and global commercialization capabilities.

Eli Lilly and Company holds 17% share, supported by innovative migraine biologics, strong clinical evidence, and wide physician adoption.

AbbVie Inc. holds 14% share, leveraging its neuroscience portfolio, sustained R&D investment, and established presence in chronic migraine management.

Teva Pharmaceuticals holds 12% share, driven by its CGRP antagonist offerings, global generics strength, and cost-effective migraine treatment options.

Pfizer Inc. holds 10% share, supported by strategic partnerships, targeted migraine therapeutics, and strong global distribution networks.

Lundbeck holds 8% share, focusing on central nervous system disorders and specialized migraine drug development.

Endo Pharmaceuticals Inc. holds 6% share, leveraging branded and generic migraine medications with established market presence.

Tonix Pharmaceuticals holds 5% share, driven by pipeline-stage migraine therapies and innovation in CNS drug delivery approaches.

Impel Pharmaceuticals Inc. holds 4% share, supported by proprietary nasal delivery technology enabling rapid migraine relief.

Currax Pharmaceuticals holds 3% share, focusing on niche migraine products and targeted commercialization strategies.

Others collectively hold 0-5% share, comprising regional and specialty pharmaceutical companies active in migraine therapeutics.

Emerging Players
Biohaven Pharmaceuticals | Axsome Therapeutics | Others

Emerging Players Highlights
Biohaven Pharmaceuticals is advancing next-generation migraine treatments through innovative CGRP pathway modulation and late-stage clinical assets.

Axsome Therapeutics is gaining traction with differentiated CNS-focused migraine candidates and novel mechanisms of action aimed at unmet patient needs.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=migraine-drugs-market?sai-v

Market Drivers
- Rising global prevalence of migraine disorders driven by lifestyle factors, stress, and increased disease awareness.

- Growing adoption of advanced migraine therapies including CGRP inhibitors, gepants, and ditans offering improved efficacy and tolerability over older treatments.

- Increasing demand for preventive migraine medications to reduce attack frequency and severity.

- Expansion of diagnostic capabilities and healthcare access improving migraine detection and treatment initiation.

- Supportive clinical guidelines and favorable reimbursement policies encouraging uptake of novel migraine drugs.

Industry Developments
- Launch of next-generation CGRP monoclonal antibodies and small-molecule CGRP receptor antagonists for both preventive and acute migraine management.

- Development of combination therapies integrating multiple mechanisms to address treatment-resistant migraine.

- Strategic partnerships, licensing agreements, and acquisitions aimed at strengthening migraine drug portfolios.

- Growing emphasis on real-world evidence and patient-centric outcomes to inform treatment strategies and regulatory decisions.

- Increasing integration of digital health tools, wearables, and telehealth platforms to support migraine tracking and therapeutic adherence.

Regional Insights
North America - 42% share: "Driven by high migraine prevalence, strong healthcare infrastructure, rapid adoption of innovative therapies, and favorable payer coverage."

Europe - 28% share: "Supported by growing awareness, established treatment guidelines, and increasing use of advanced migraine medications."

Asia Pacific - 23% share: "Fueled by rising disease burden, expanding healthcare access, improving diagnostic capabilities, and growing treatment adoption."

Latin America - 5% share: "Driven by improving access to migraine care and growing interest in novel therapeutic options."

Middle East & Africa - 2% share: "Supported by increasing healthcare investments, rising awareness of neurological disorders, and gradual adoption of modern migraine treatments."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/migraine-drugs-market?sai-v

Key Segments
By Drug Class
Triptans represent a major drug class due to their established efficacy in acute migraine management and widespread clinical use. NSAIDs and acetaminophen continue to be commonly prescribed for mild to moderate migraine relief owing to their accessibility and cost-effectiveness. CGRP monoclonal antibodies and CGRP small molecule antagonists are witnessing rapid growth, driven by their targeted mechanism of action and increasing adoption for preventive migraine therapy. Acetylcholine inhibitors and neurotoxins are gaining traction for chronic migraine management. Antidepressants are used primarily for preventive treatment in patients with comorbid conditions, while ergot alkaloids maintain a niche role. Other drug classes include antiemetics and emerging combination therapies.

By Route of Administration
Oral administration dominates the market due to patient convenience and wide availability of oral formulations. Injectable routes hold a significant share, particularly for biologics, neurotoxins, and severe or chronic migraine treatments. Other routes, including nasal sprays and transdermal systems, are gaining adoption to improve rapid onset and patient compliance.

By Age Group
The adult population accounts for the largest share, driven by high migraine prevalence and active healthcare-seeking behavior. The geriatric segment is expanding steadily due to increasing life expectancy and better diagnosis of migraine in older adults. Pediatric patients represent a smaller but important segment, supported by rising awareness and availability of age-appropriate formulations.

By Distribution Channel
Retail pharmacies dominate the distribution landscape due to ease of access and widespread presence. Hospital pharmacies play a critical role in managing severe cases and administering injectable therapies. Online pharmacies are experiencing strong growth, supported by increasing digital adoption, home delivery services, and improved access to chronic migraine medications.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.